Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CHRM4 | P08173 | 1/20 | 0.40 |
| ▸ | CHRM3 | P20309 | 1/20 | 0.40 |
| ▸ | ATM | Q13315 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | NTMT1 | Q9BV86 | 1/20 | 0.36 |
| ▸ | CCNE1 | P24864 | 7/20 | 0.34 |
| ▸ | CDK2 | P24941 | 7/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.34 |
| ▸ | GSK3B | P49841 | 3/20 | 0.33 |
| ▸ | BCHE | P06276 | 1/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.33 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.33 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25247324 | 0.86 | CHRM3 (0.46) | CHRM4CHRM3DPP4NTMT1SMN1; SMN2 | |
| SCHEMBL3247378 | 0.83 | SMN1; SMN2 (0.54) | ATMNTMT1SMN1; SMN2 | |
| SCHEMBL3243697 | 0.83 | SMN1; SMN2 (0.54) | ATMNTMT1SMN1; SMN2 | |
| SCHEMBL23089331 | 0.81 | CHRM3 (0.46) | CHRM4CHRM3ATMDPP4SMN1; SMN2 | |
| SCHEMBL7815595 | 0.79 | EPHX1 (0.42) | DPP4CCNE1CDK2SMN1; SMN2GSK3B | |
| Methane SCHEMBL27968861 | 0.78 | EPHX1 (0.41) | DPP4CCNE1CDK2SMN1; SMN2GSK3B | |
| SCHEMBL10154672 | 0.78 | CHRM1 (0.44) | CHRM4CHRM3ATMSMN1; SMN2BCHE | |
| SCHEMBL4464249 | 0.76 | BRD4 (0.45) | DPP4CCNE1CDK2SMN1; SMN2GSK3B | |
| SCHEMBL12669754 | 0.76 | EPHX1 (0.48) | DPP4NTMT1SMN1; SMN2LMNA | |
| SCHEMBL18587782 | 0.76 | CHRM3 (0.42) | CHRM4CHRM3ATMSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | SCHRÖDINGER, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230167110-A1 | 6-HETEROARYLOXY BENZIMIDAZOLES AND AZABENZIMIDAZOLES AS JAK2 INHIBITORS | JAK2, JAK3, STAT5B | CHRM4 4875/4885CHRM3 4861/4885ATM 562/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.